German company Grünenthal has acquired US-based Valinor Pharma along with its product Movantik (naloxegol) for approximately $250 million.

Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Gross sales from the drug in the United States (US) reached over $200 million in 2023.

“As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio,” said Gabriel Baertschi, CEO, Grünenthal. “The acquisition of Valinor Pharma strengthens our footprint in the US, the most important growth market for Grünenthal.”

Marv Kelly, President of Grünenthal US, added: “We are excited to welcome Valinor and expand our portfolio offering to pain specialists with Movantik.”

Grünenthal acquired the product in Europe (branded Moventig outside of the US) in 2023 as part of a joint venture with Kyowa-Kirin. The acquisition of Valinor makes Grünenthal the worldwide owner of the brand (ex-Canada).

Since 2017, Grünenthal has invested more than €2 billion ($2.18 billion) in M&A transactions. The company has acquired several established medicines, including Nebido, the European rights to Crestor and Nexium, as well as the global rights to Vimovo (excluding the US and Japan), Qutenza and Zomig (excluding Japan).

In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US. In 2023, the company employed around 4,400 people and achieved revenues of €1.8 billion ($1.96 billion).

Diana Spencer, Senior Digital Content Editor, DDW